Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets

被引:3
|
作者
Morton, Terri [1 ]
Franke, Ryan [1 ]
Devarakonda, Krishna [1 ]
机构
[1] Mallinckrodt Pharmaceut, Clin Pharmacol, Hazelwood, MO USA
关键词
acetaminophen; acute pain; extended release; fixed-dose combination; population pharmacokinetics; oxycodone; opioid analgesic; PAIN; PREVALENCE; OPIOIDS; AGE;
D O I
10.1111/papr.12329
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
ObjectiveTo examine whether biphasic immediate-release (IR)/extended-release (ER) oxycodone (OC)/acetaminophen (APAP) 7.5/325-mg tablets have clinically relevant variability in population pharmacokinetics (PK). DesignPost hoc analysis of 2 phase 1 randomized, open-label, multiple-dose crossover studies. SettingSingle contract research organization clinic. SubjectsMen and women aged 18 to 55years with a body mass index of 19 to 30kg/m(2) and body weight 59kg. MethodsFasted participants (N=96) received 2 tablets of IR/ER OC/APAP 7.5/325mg (total dose, 15/650mg) every 12hours for 4.5days. Population PK analysis was performed using nonlinear mixed effects modeling and evaluated 6 population variables. ResultsThe average PK estimates for OC were 75L/hour for clearance (CL/F), 756L for volume of distribution (V/F), and 0.581per hour for absorption rate constant (K-a). Body weight was a statistically significant source of variability in V/F for OC at steady state. Average estimates for APAP were 25L/hour for CL/F and 119L for V/F. Sex was identified as a statistically significant source of variability in CL/F with predicted values for APAP of 25L/hour in men and 21L/hour in women. Body weight affected variability in V/F, with a predicted value of 193L in men and 174L in women for a 72-kg participant at steady state. ConclusionsDose adjustments of <50% are not clinically relevant for IR/ER OC/APAP 7.5/325-mg tablets considering the approved dose of 1 to 2 tablets every 8 to 12hours; thus, adjustment may be necessary for large deviations from normal body weight but not for sex.
引用
收藏
页码:730 / 736
页数:7
相关论文
共 29 条
  • [21] Comparative Pharmacokinetics of a Once-Daily Tramadol Extended-Release Tablet and an Immediate-Release Reference Product Following Single-Dose and Multiple-Dose Administration
    Karhu, David
    Fradette, Caroline
    Potgieter, Maria Alida
    Ferreira, Maria M.
    Terblanche, Johann
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (05) : 544 - 553
  • [22] Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials
    Wilson, Jacquelyn G.
    Bass, Almasa
    Pixton, Glenn C.
    Wolfram, Gernot
    Rauck, Richard L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (01) : 91 - 99
  • [23] Single- and Multiple-Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Volunteers: A Comparison of Extended-Release Oxycodone With Sequestered Naltrexone 40 mg Twice Daily to OxyContin 40 mg Twice Daily and Extended-Release Oxycodone With Sequestered Naltrexone 80 mg Once Daily
    Gandelman, Kuan
    Lamson, Michael
    Bramson, Candace
    Matschke, Kyle
    Salageanu, Joanne
    Malhotra, Bimal
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (05): : 361 - 369
  • [24] Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
    Kim, Hyun Chul
    Yoon, Deok Yong
    Lee, SeungHwan
    Jang, In-Jin
    Hong, Jang Hee
    Kim, JaeWoo
    TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2022, 30 (02) : 112 - 119
  • [25] Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects
    Xu, M. J.
    Zou, C.
    Chu, J. H.
    Wu, T.
    Liu, S. J.
    Zhang, J.
    Chen, M.
    Liu, F.
    Xiong, N. N.
    Ju, W. Z.
    Tan, H. S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (03) : 237 - 246
  • [26] Pharmacokinetic profile of extended-release versus immediate-release oral naproxen sodium after single and multiple dosing under fed and fasting conditions: two randomized, open-label trials
    Laurora, Irene
    Wang, Yuan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (10) : 750 - 760
  • [27] Pharmacokinetics of Extended-Release Versus Conventional Tramadol/Acetaminophen Fixed-Dose Combination Tablets: An Open-Label, 2-Treatment, Multiple-Dose, Randomized-Sequence Crossover Study in Healthy Korean Male Volunteers
    Yi, SoJeong
    Chung, Yong-ju
    Kim, Tae-Eun
    Shin, Hyun-Suk
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Jang, In-Jin
    Shin, Sang-Goo
    Yu, Kyung-Sang
    CLINICAL THERAPEUTICS, 2011, 33 (06) : 728 - 737
  • [28] Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist
    Toyama, Kaoru
    Uchida, Naoki
    Ishizuka, Hitoshi
    Sambe, Takehiko
    Kobayashi, Shinichi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09) : 975 - 984
  • [29] Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®)
    Hsu, Ann
    Yao, Hsuan-Ming
    Gupta, Suneel
    Modi, Nishit B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09) : 995 - 1003